Latest News
Retension Pharmaceuticals, Inc.
- Retension Pharmaceuticals, Inc. Estimates – NASDAQ:RTSN
- Form 4 Retension Pharmaceuticals: Eric L. Keller (Director, CEO) For: 22 October
- Dilution adjustment of Retension Pharmaceuticals Inc – FWB:TL4
- Non-controlling/minority interest of Retension Pharmaceuticals, Inc. – NASDAQ:RTSN
- Retension Pharmaceuticals, Inc. Income Statement – NASDAQ:RTSN
- Retension Pharmaceuticals, Inc. Financial Statements – NASDAQ:RTSN
- Retension Pharmaceuticals exceeds target with $45M IPO
- Roundup: TRexBio & Retension Pharmaceuticals Announce IPO Pricing
- Form 4 Retension Pharmaceuticals For: 8 October By Investing.com
- Retension Pharmaceuticals, Clinical-Stage Developer of Hypertension Therapies, Files for Nasdaq Capital Market IPO
- Retension Pharmaceuticals prices IPO at $12 per share on Nasdaq
- Retension Pharmaceuticals prices upsized IPO at $12 per share
Headlines from the last 30 days, linking to the original publishers. See all market news →